TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1746-1596
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome ; volume:16 ; number:1 ; day:31 ; month:10 ; year:2021 ; pages:1-8 ; date:12.2021
Diagnostic pathology ; 16, Heft 1 (31.10.2021), 1-8, 12.2021
- Urheber
-
Niparuck, Pimjai
Police, Pornnapa
Noikongdee, Phichchapha
Siriputtanapong, Kanchana
Limsuwanachot, Nittaya
Rerkamnuaychoke, Budsaba
Chuncharunee, Suporn
Siriboonpiputtana, Teerapong
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13000-021-01162-8
- URN
-
urn:nbn:de:101:1-2022010917480015929340
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Niparuck, Pimjai
- Police, Pornnapa
- Noikongdee, Phichchapha
- Siriputtanapong, Kanchana
- Limsuwanachot, Nittaya
- Rerkamnuaychoke, Budsaba
- Chuncharunee, Suporn
- Siriboonpiputtana, Teerapong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Retraction Note: Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia
Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Functional classification of TP53 mutations in acute myeloid leukemia
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Retraction Note: Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia
Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Functional classification of TP53 mutations in acute myeloid leukemia
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
Retraction Note: Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia
Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups